Canada Approves New Alzheimer's Drug That Slows Disease

For the first time in decades, people facing early Alzheimer's disease have a treatment that actually slows the disease down, not just manages symptoms.

Health Canada approved Kisunla (donanemab) in May 2026, giving new hope to Canadians with mild cognitive impairment or early Alzheimer's. The once-monthly infusion works differently than anything before it by targeting and removing amyloid plaques, the protein clumps in the brain that cause memory and thinking problems.

What makes this treatment groundbreaking is that patients don't need it forever. Once brain scans show the plaques are cleared, treatment stops. Some patients completed therapy in just six months, while nearly half finished within a year.

The numbers tell an encouraging story. In clinical trials, Kisunla reduced the risk of progressing to the next disease stage by 40% in the indicated population. Patients in the earliest stages saw a 35% slowing of decline in memory, thinking, and daily functioning over 18 months.

Lilly Canada spent 35 years researching Alzheimer's before reaching this milestone. The treatment has now been approved in 48 countries worldwide, expanding access to millions of patients and families desperate for real solutions.

The timing couldn't be more critical. More than 770,000 Canadians currently live with Alzheimer's, and that number is projected to double by 2050. The disease costs Canada an estimated $40 billion annually and ranks among the leading causes of death and disability.

The Ripple Effect

This approval ripples far beyond individual patients. Families who've watched loved ones slowly disappear into dementia now have a tool to buy precious time. Dr. Sharon Cohen from Toronto Memory Program explains that people in early Alzheimer's stages still live independently and lead full lives but often dread what's coming next.

Christina Scicluna, CEO of the Alzheimer Society of Canada, calls the authorization "a hopeful milestone." While not a cure, it demonstrates how decades of research and advocacy translate into tangible progress for patients.

The treatment does require careful monitoring. Patients need MRI scans to watch for brain swelling or bleeding, side effects that usually resolve but can occasionally be serious. The therapy isn't appropriate for everyone, particularly those with certain genetic profiles that increase risk.

Lilly Canada promises this is just the beginning, with plans to work with governments and healthcare systems to ensure Canadians can access this advanced treatment.

After decades of failed Alzheimer's drugs, science has finally delivered a therapy that gives people more time with their memories, their independence, and their loved ones.